China’s biotechnology sector is undergoing a profound transformation, evolving from rapid expansion into a new phase defined by quality, global relevance, and sustained innovation. What was once an emerging segment is now a core pillar of China’s high-value technology economy, with measurable progress across drug discovery, clinical development, regulatory advancement, and international collaboration. According to the latest Clarivate report, Mainland China Biopharma Innovation 2.0: From Rapid Growth to Quality-Driven Development, China became the world’s second-largest source of first launches of new molecular entities (NMEs) in 2024, accounting for 18 percent of the global total. The findings mark a significant milestone ...

China’s biotechnology sector has reached an unprecedented level of growth, establishing itself as a global hub of innovation, scientific excellence, and transformative therapies. This rise is the result of years of dedicated research, strategic investment, and the cultivation of a robust ecosystem that supports talent, technology, and entrepreneurship. Chinese biotech companies are now at the forefront of oncology, obesity treatments, and other breakthrough medical solutions, demonstrating both scientific ingenuity and commercial success. Leading the charge is Akeso, a biotech company that has developed ivonescimab, a therapy generating significant global attention for its potential in cancer treatment. Under the guidance of ...

China’s “Healthy China 2030” blueprint is widely known as a major public health initiative. But its deeper significance is far more strategic. Behind the healthcare reforms is a comprehensive effort to build a next-generation biotechnology and digital health industry that strengthens national resilience, unlocks high-quality economic growth, and positions China for long-term technological leadership. As regional cooperation intensifies through APEC and other multilateral platforms, China is bringing forward a new vision: health as a driver of innovation, industrial upgrading, and shared regional development. Unlike short-term economic narratives, HC2030 represents a long-term structural transformation anchored in technology, science, and talent. A ...

China is pushing the boundaries of biotechnology with a spirit of bold exploration and scientific responsibility. Through major advancements in gene-edited animal research, Chinese scientists are accelerating the discovery of therapies that could transform global medicine — and in the process, strengthen the nation’s position as a world leader in biotech innovation. A Landmark Discovery in Beijing In a research laboratory at Tsinghua University, Professor Jia Yichang witnessed a moment that redefined his career — and perhaps the future of neurological medicine. A young pig, genetically modified to model amyotrophic lateral sclerosis (ALS), began to show symptoms of the disease ...

In the global race to develop next-generation medicines, speed, precision, and reliability are paramount. Continuing to establish its role at the forefront of China’s innovation in the life sciences, WuXi Biologics has launched TrueSite TI™, a state-of-the-art cell line platform poised to transform the landscape of biopharmaceutical development. This fourth-generation technology isn’t just an incremental update, it represents a fundamental leap forward in how complex protein therapies are created, promising to bring breakthrough treatments to patients faster than ever before. The Precision Revolution: Targeted Integration At the heart of TrueSite TI™ lies Targeted Integration (TI), a sophisticated cellular engineering technique ...

China’s biotech sector is making global headlines as a new wave of licensing deals reshapes how innovative drug candidates reach international markets. At the center of this trend is the NewCo licensing model, which has rapidly gained traction and positioned Chinese biotechs as key beneficiaries of cross-border pharmaceutical collaboration. Unlike traditional licensing agreements, where rights are transferred directly to a major pharmaceutical company, the NewCo model creates a newly formed entity, often backed by global venture investors, outside of China. The original biotech developer then retains equity in this NewCo, allowing it to share in future international revenues while avoiding ...

When Michelle Xia returned to China in 2008 after two decades abroad, she didn’t plan on becoming the CEO of one of the country’s most exciting biotech firms. But her decision to co-found Akeso in 2012 with just $3 million in angel funding would ultimately place her company and China’s entire biotech sector on the global map. At the time, China’s pharmaceutical industry was still dominated by generics. The infrastructure for innovative drug development barely existed, and few companies dared to invest in original discovery work. Talent and capital were scarce, and skepticism was widespread among doctors, investors, and regulators. ...

China’s biopharma sector is on track to become the world’s third-largest market for innovative drugs by 2028, according to McKinsey & Company’s upcoming Asia Biopharma Report. The projection highlights the country’s transition from being a generics-heavy pharmaceutical market to an emerging global powerhouse in drug innovation. In 2023, China’s pharmaceutical market reached $125 billion, with the innovative drug segment expanding at an average annual growth rate of 16%. While multinational pharmaceutical companies controlled around 75% of the innovative drug market last year, McKinsey forecasts their share will fall to 60% by 2028 as domestic firms gain ground. This shift is ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company headquartered in Suzhou, has received clearance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to begin a registrational Phase III clinical trial of lisaftoclax (APG-2575) for the first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS). The trial, known as GLORA-4 (NCT06641414), was originally approved by China’s Center for Drug Evaluation (CDE) in 2024, underscoring the multinational scope and accelerated pace of the program. Lisaftoclax is a novel, orally administered Bcl-2 selective inhibitor designed to restore apoptosis in cancer cells by blocking the anti-apoptotic protein Bcl-2. ...

After a challenging two-year slump, China’s pharmaceutical outsourcing industry is showing signs of a powerful comeback, and the WuXi group is at the heart of it. WuXi Biologics (2269.HK), the flagship biologics services provider under the WuXi umbrella, issued a profit alert on July 24 projecting a 56% surge in net profit for the first half of 2025, alongside 16% revenue growth. The positive guidance followed upbeat forecasts from its sister companies, WuXi AppTec and WuXi XDC, all of which highlight renewed global demand for China’s high-end pharmaceutical manufacturing capabilities. The news sent WuXi Biologics shares rallying nearly 10% over ...